Angela Napoli

Angela Napoli

Auto-generated profile, based on publicly available information

Angela Napoli

Israelitico Hospital, 00044 Rome, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2020 in Diabetologia
Verified
Journal Article
Open access
PDF file
TGthe INSPIRED research group
the INSPIRED research group
AEAoife Egan
Aoife Egan
DBDelia Bogdanet
Delia Bogdanet
TGTomás P. Griffin
Tomás P. Griffin
OKOratile Kgosidialwa
Oratile Kgosidialwa
FDFidelma Dunne
Fidelma Dunne
Aims/hypothesis: The aim of this systematic review was to develop core outcome sets (COSs) for trials evaluating interventions for the prevention or treatment of gestational diabetes mellitus (GDM). Methods: We identified previously reported outcomes through a systematic review of the literature. These outcomes were presented to key stakeholders (including patient representatives, researchers and clinicians) for prioritisation using a three-round, e-Delphi study. A priori consensus criteria informed which outcomes were brought forward for discussion at a face-to-face consensus meeting where the COS was finalised. Results: Our review identified 74 GDM prevention and 116 GDM treatment outcomes, which were presented to stakeholders in round 1 of the e-Delphi study. Round 1 was completed by 173 stakeholders, 70% (121/173) of whom went on to complete round 2; 84% (102/121) of round 2 responders completed round 3. Twenty-two GDM prevention outcomes and 30 GDM treatment outcomes were discussed at the consensus meeting. Owing to significant overlap between included prevention and treatment outcomes, consensus meeting stakeholders agreed to develop a single prevention/treatment COS. Fourteen outcomes were included in the final COS. These consisted of six maternal outcomes (GDM diagnosis, adherence to the intervention, hypertensive disorders of pregnancy, requirement and type of pharmacological therapy for hyperglycaemia, gestational weight gain and mode of birth) and eight neonatal outcomes (birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, neonatal hypoglycaemia, neonatal death and stillbirth). Conclusions/interpretation: This COS will enable future GDM prevention and treatment trials to measure similar outcomes that matter to stakeholders and facilitate comparison and combination of these studies. Trial registration: This study was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/studies/details/686/

3 August 2021 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
OKOratile Kgosidialwa
Oratile Kgosidialwa
DBDelia Bogdanet
Delia Bogdanet
AEAoife Egan
Aoife Egan
POPaula M. O’shea
Paula M. O’shea
CNChristine Newman
Christine Newman
MLMary R. Loeken
Mary R. Loeken
Objective: To develop a core outcome set (COS) for randomised controlled trials (RCTs) evaluating the effectiveness of interventions for the treatment of pregnant women with pregestational diabetes mellitus (PGDM).Design: A consensus developmental study.Setting: International.Population: Two hundred and five stakeholders completed the first round.Methods: The study consisted of three components. (1) A systematic review of the literature to produce a list of outcomes reported in RCTs assessing the effectiveness of interventions for the treatment of pregnant women with PGDM. (2) A three‐round, online eDelphi survey to prioritise these outcomes by international stakeholders (including healthcare professionals, researchers and women with PGDM). (3) A consensus meeting where stakeholders from each group decided on the final COS.Main outcome measures: All outcomes were extracted from the literature.Results: We extracted 131 unique outcomes from 67 records meeting the full inclusion criteria. Of the 205 stakeholders who completed the first round, 174/205 (85%) and 165/174 (95%) completed rounds 2 and 3, respectively. Participants at the subsequent consensus meeting chose 19 outcomes for inclusion into the COS: trimester‐specific haemoglobin A1c, maternal weight gain during pregnancy, severe maternal hypoglycaemia, diabetic ketoacidosis, miscarriage, pregnancy‐induced hypertension, pre‐eclampsia, maternal death, birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, mode of birth, shoulder dystocia, neonatal hypoglycaemia, congenital malformations, stillbirth and neonatal death.Conclusions: This COS will enable better comparison between RCTs to produce robust evidence synthesis, improve trial reporting and optimise research efficiency in studies assessing treatment of pregnant women with PGDM.Tweetable 165 key stakeholders have developed #Treatment #CoreOutcomes in pregnant women with #diabetes existing before pregnancy.

29 May 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
AGAnnalisa Giandalia
Annalisa Giandalia
Giuseppina Tiziana RussoGiuseppina Tiziana Russo
Giuseppina Tiziana Russo
PRPatrizia Ruggeri
Patrizia Ruggeri
AGAnnalisa Giancaterini
Annalisa Giancaterini
EBElisabetta Brun
Elisabetta Brun
ANAngela Napoli
Angela Napoli
Objective Obesity is a growing emergency in type 1 diabetes (T1D). Sex differences in obesity prevalence and its clinical consequences in adult T1D subjects have been poorly investigated. The aim of this study was to investigate the prevalence of obesity and severe obesity, clinical correlates, and potential sex differences in a large cohort of T1D subjects participating to the AMD (Associazione Medici Diabetologi) Annals Initiative in Italy. Research Design and Methods The prevalence of obesity [body mass index(BMI) ≥30 kg/m2] and severe obesity (BMI ≥ 35 kg/m2) according to sex and age, as well as obesity-associated clinical variables, long-term diabetes complications, pharmacological treatment, process indicators and outcomes, and overall quality of care (Q-score) were evaluated in 37 436 T1D subjects (45.3% women) attending 282 Italian diabetes clinics during 2019. Results Overall, the prevalence of obesity was similar in the 2 sexes (13.0% in men and 13.9% in women; mean age 50 years), and it increased with age, affecting 1 out of 6 subjects ages >65 years. Only severe obesity (BMI >35 kg/m2) was more prevalent among women, who showed a 45% higher risk of severe obesity, compared with men at multivariate analysis. Cardiovascular disease risk factors (lipid profile, glucose, and blood pressure control), and the overall quality of diabetes care were worse in obese subjects, with no major sex-related differences. Also, micro- and macrovascular complications were more frequent among obese than nonobese T1D men and women. Conclusions Obesity is a frequent finding in T1D adult subjects, and it is associated with a higher burden of cardiovascular disease risk factors, micro- and macrovascular complications, and a lower quality of care, with no major sex differences. T1D women are at higher risk of severe obesity.

4 May 2021 in Frontiers in Psychology
Verified
Journal Article
Open access
FMFrancesco Marchini
Francesco Marchini
ACAndrea Caputo
Andrea Caputo
ACAlessio Convertino
Alessio Convertino
ANAngela Napoli
Angela Napoli
Psychodynamics in Diabetes: The Relevance of Deepening the Symbolic in Treatment Adherence

1 December 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MBMario Brinciotti
Mario Brinciotti
MMMaria Matricardi
Maria Matricardi
ACAntonietta Colatrella
Antonietta Colatrella
FTFrancesco Torcia
Francesco Torcia
FFFrancesco Fallucca
Francesco Fallucca
ANAngela Napoli
Angela Napoli
Il diabete materno in gravidanza predispone il neonato a un maggior rischio di problemi cognitivi, soprattutto se è stato più difficoltoso il controllo metabolico. Un campione di 40 nati di madre diabetica è stato studiato all’ età di 2 mesi attraverso la somministrazione della Scala di Sviluppo Psicomotorio (Test di Brunet- Lezine) e sottoponendoli a registrazione dei Potenziali Evocati Visivi. E’ stato riscontrato un significativo aumento di latenza dei PEV rispetto ai controlli mentre il Quoziente di Sviluppo risultava mediamente nella norma. I PEV si dimostrano uno strumento utile e sensibile per il monitoraggio precoce del livello di maturazione cerebrale e possono costituire un marker per la valutazione del rischio di problemi di sviluppo cognitivo in età successive

1 January 1996 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
FFF Fallucca
F Fallucca
ESE Sciullo
E Sciullo
ANA Napoli
A Napoli
GCG Cardellini
G Cardellini
AMA Maldonato
A Maldonato
Thanks to the widespread use of amniocentesis, glucose, insulin, and C peptide have often been measured in amniotic fluid (AF) during late gestation, but little is known about their concentrations during early pregnancy. To better understand early fetal beta-cell function under normal conditions and in the presence of maternal diabetes, we measured glucose, insulin, and C peptide in the AF collected during weeks 15-22 in 77 healthy and 9 diabetic women undergoing amniocentesis for clinical indications and compared the results with those obtained during late pregnancy (weeks 34-36). The AF C peptide concentration was higher in diabetic women (102 +/- 53 vs. 38 +/- 2 pmol/L), in the women with a family history of diabetes (41 +/- 6 vs. 35 +/- 2 pmol/L), after the 19th week of gestation (46 +/- 5 vs. 35 +/- 2 pmol/L; in the presence of lower glucose concentrations), and in the presence of maternal plasma glucose levels greater than 5.56 mmol/L (42 +/- 3.5 vs. 34 +/- 2 pmol/L). The comparison between early and late gestation showed decreasing glucose and increasing C peptide concentrations in both healthy and diabetic women (in the latter, C peptide values were always 3 times higher), whereas the insulin concentration was increased in late gestation only in diabetic women. The AF C peptide/insulin molar ratio increased throughout pregnancy in both healthy (from 0.97 +/- 0.06 to 4.3 +/- 1.2) and diabetic (from 2.9 +/- 1.1 to 13.2 +/- 1.6) women. These parallel changes suggest that the fetal clearance and/or degradation of insulin and C peptide may greatly change during both normal and diabetic gestation.